Characteristics, Healthcare Utilization, and Costs of Medicare Patients Receiving CAR T-Cell Therapy

Video

Karl M. Kilgore, PhD, senior research scientist, Avalere Health, discusses real-world data regarding Medicare patients with non-Hodgkin lymphoma receiving CAR T-cell therapy.

Karl M. Kilgore, PhD, senior research scientist, Avalere Health, discusses real-world data regarding Medicare patients with non-Hodgkin lymphoma receiving CAR T-cell therapy.

In the analysis, investigators compared healthcare utilization, costs, and outcomes pre- and post-treatment with either axicabtagene ciloleucel (axi-cel; Yescarta) or tisagenlecleucel (Kymriah). Patients included in the analysis had an average age of 70 years, which is significantly older than the patients enrolled in the pivotal trials, notes Kilgore. Notably, 43% of patients had ≥1 comorbidity that would have rendered them ineligible for participation in these clinical trials.

Even so, investigators found a significantly lower hospital stay rate following treatment with CAR T-cell therapy. Moreover, the number of emergency department visits was reduced by 30%, and the total healthcare costs, excluding the cost of CAR T-cell therapy, was reduced by approximately 37%. Taken collectively, these results suggest that older patients with multiple comorbidities can be treated successfully with CAR T-cell therapy, concludes Kilgore.

Related Videos
Shivaani Kummar, MBBS, FACP, Margaret and Lester DeArmond Endowed Chair of Cancer Research, Professor and Division Head, Division of Hematology/Medical Oncology, Oregon Health & Science University School of Medicine; co-director, Center for Experimental Therapeutics, co-deputy director, Knight Cancer Institute
Andre Goy, MD
Wenxin (Vincent) Xu, MD,
Guenther Koehne, MD, PhD
Alessandro Villa, DDS, PhD, MPH
Joseph Mikhael, MD
Michael Richardson, MD
Minesh Mehta, MD
Ruben Olivares, MD
Phillip J. Koo, MD